Related Experiment Video

Updated: May 22, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Getting to the finish line with mTORC1-targeted therapy

Elizabeth Henske1

  • 1Brigham and Women’s Hospital, Boston, Massachusetts 02115, USA. ehenske@partners.org

The Journal of Clinical Investigation
|May 25, 2012
PubMed

Insights

Inhibition of the mammalian target of rapamycin complex 1 (mTORC1) pathway via Raptor deficiency blocks leukemia cell differentiation and prolongs survival. However, it also allows leukemia-initiating cells to persist in a dormant state.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Signaling

Background:

  • The mammalian target of rapamycin (mTOR) pathway is frequently activated in human cancers, making it a potential therapeutic target.
  • Genetic complexity of the mTOR pathway complicates the use of pharmacologic inhibitors.
  • The role of mTORC1 in leukemia requires further elucidation.

Purpose of the Study:

  • To investigate the role of mTORC1 in leukemia using a mouse model.
  • To understand the effects of inhibiting mTORC1 on leukemia cell differentiation and survival.

Main Methods:

  • Generation of mice deficient in Raptor, a key effector protein of mTORC1.
  • Analysis of leukemia cell differentiation, survival, and the persistence of leukemia-initiating cells in these mice.

Main Results:

  • Raptor deficiency leads to mTORC1 inhibition.
  • mTORC1 inhibition blocks leukemia cell differentiation and extends survival.
  • A subpopulation of leukemia-initiating cells persists in a dormant state.

Conclusions:

  • mTORC1 plays a critical role in leukemia cell differentiation and survival.
  • Targeting mTORC1 may offer therapeutic benefits in leukemia but requires careful consideration of dormant cell populations.
  • Further research into the molecular mechanisms of dormancy is necessary for effective therapeutic strategies.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...